PL3669892T3 - Kompozycja do zastosowania w metodzie immunostymulacyjnej - Google Patents

Kompozycja do zastosowania w metodzie immunostymulacyjnej

Info

Publication number
PL3669892T3
PL3669892T3 PL20155567.9T PL20155567T PL3669892T3 PL 3669892 T3 PL3669892 T3 PL 3669892T3 PL 20155567 T PL20155567 T PL 20155567T PL 3669892 T3 PL3669892 T3 PL 3669892T3
Authority
PL
Poland
Prior art keywords
composition
immunostimulatory method
immunostimulatory
Prior art date
Application number
PL20155567.9T
Other languages
English (en)
Inventor
David Charles Jackson
Amabel Tan
Weiguang Zeng
Original Assignee
Ena Respiratory Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010904284A external-priority patent/AU2010904284A0/en
Application filed by Ena Respiratory Pty Ltd filed Critical Ena Respiratory Pty Ltd
Publication of PL3669892T3 publication Critical patent/PL3669892T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20155567.9T 2010-09-22 2011-09-22 Kompozycja do zastosowania w metodzie immunostymulacyjnej PL3669892T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010904284A AU2010904284A0 (en) 2010-09-22 Novel Immunostimulatory Method
AU2011902408A AU2011902408A0 (en) 2011-06-20 Novel immunstimulatory method

Publications (1)

Publication Number Publication Date
PL3669892T3 true PL3669892T3 (pl) 2024-10-07

Family

ID=45873313

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11826223T PL2618842T3 (pl) 2010-09-22 2011-09-22 Nowa metoda immunostymulacyjna
PL20155567.9T PL3669892T3 (pl) 2010-09-22 2011-09-22 Kompozycja do zastosowania w metodzie immunostymulacyjnej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11826223T PL2618842T3 (pl) 2010-09-22 2011-09-22 Nowa metoda immunostymulacyjna

Country Status (10)

Country Link
US (5) US9676819B2 (pl)
EP (3) EP2618842B1 (pl)
JP (6) JP2013537892A (pl)
CN (2) CN103189072B (pl)
AU (1) AU2011305061B2 (pl)
CA (1) CA2811957C (pl)
DK (1) DK2618842T3 (pl)
ES (2) ES2735274T3 (pl)
PL (2) PL2618842T3 (pl)
WO (1) WO2012037612A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
EP3604271A1 (en) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptides for amino acid and peptide conjugates and conjugation process
US20170274068A1 (en) * 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CN110461351B (zh) * 2017-03-31 2024-03-26 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
WO2019119069A1 (en) * 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
US20220347146A1 (en) * 2019-09-04 2022-11-03 Axelia Oncology Pty Ltd Cancer treatment
AU2020340468A1 (en) * 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer immunotherapy

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
NZ520976A (en) 1999-11-19 2005-01-28 Csl Ltd Vaccine compositions
HU230847B1 (en) 2000-05-19 2018-08-28 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
EP1382352A1 (de) * 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
BR0313101A (pt) 2002-08-12 2005-06-28 Queensland Inst Med Res Novos lipopeptìdeos imunogênicos que compreendem epitopos de linfócitos t-helper e linfócitos t citotóxicos (ctl), e métodos para sua produção e uso
AU2003250586B2 (en) * 2002-08-12 2010-09-23 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
CN1921877A (zh) * 2004-01-16 2007-02-28 悉生物有限公司 陪伴蛋白10对Toll样受体诱导的细胞因子和趋化因子分泌的调节
US20060002941A1 (en) 2004-01-23 2006-01-05 Vievax Corp. Compositions comprising immune response altering agents and methods of use
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP2460533A3 (en) 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
NZ556004A (en) * 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
CN101151280A (zh) * 2005-02-08 2008-03-26 昆士兰医学研究学院委员会 免疫原性分子
US7560436B2 (en) 2005-02-22 2009-07-14 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
EP1787660A1 (en) 2005-11-22 2007-05-23 GBF Gesellschaft für Biotechnologische Forschung mbH New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
WO2008085549A2 (en) 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
AU2014202674B2 (en) 2007-05-04 2014-08-14 Marina Biotech, Inc. Amino acid lipids and uses thereof
AU2008310313C1 (en) * 2007-10-09 2015-02-12 Ena Respiratory Pty Ltd A method of transfection and compositions therefor
WO2009137103A2 (en) 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
WO2010028246A2 (en) * 2008-09-05 2010-03-11 Id Biomedical Corporation Of Quebec Novel compositions and adjuvants
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
CN103800906B (zh) 2009-03-25 2017-09-22 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
GB0907989D0 (en) 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
EP2338521A1 (en) 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
EP3604271A1 (en) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptides for amino acid and peptide conjugates and conjugation process
US20170274068A1 (en) 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2016216593A (ja) 2015-05-19 2016-12-22 株式会社リコー 反応材、熱交換器及びケミカルヒートポンプ
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
PL3429618T3 (pl) 2016-03-16 2024-07-01 Amal Therapeutics Sa Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
CN110461351B (zh) 2017-03-31 2024-03-26 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
NL2018803B1 (en) 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
EP3676250A4 (en) 2017-08-30 2021-05-26 Auckland Uniservices Limited PEPTIDE CONJUGATES, CONJUGATION METHODS AND USES THEREOF
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
WO2019119069A1 (en) 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
US20220347146A1 (en) 2019-09-04 2022-11-03 Axelia Oncology Pty Ltd Cancer treatment
AU2020340468A1 (en) 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer immunotherapy
WO2021237291A1 (en) 2020-05-26 2021-12-02 Axelia Oncology Pty Ltd Treatment of coronavirus
JP7744936B2 (ja) 2020-06-26 2025-09-26 イーナ レスパラトリー ピーティーワイ リミテッド 分岐脂質化合物

Also Published As

Publication number Publication date
US11351114B2 (en) 2022-06-07
CN105477640A (zh) 2016-04-13
CN103189072A (zh) 2013-07-03
AU2011305061B2 (en) 2016-04-14
JP7497962B2 (ja) 2024-06-11
EP2618842A4 (en) 2014-03-26
JP2013537892A (ja) 2013-10-07
WO2012037612A1 (en) 2012-03-29
CA2811957A1 (en) 2012-03-29
JP6657507B2 (ja) 2020-03-04
ES2980738T3 (es) 2024-10-02
US11786458B2 (en) 2023-10-17
US20170246312A1 (en) 2017-08-31
US20240050364A1 (en) 2024-02-15
US20190380952A1 (en) 2019-12-19
CN105477640B (zh) 2019-09-17
US10406100B2 (en) 2019-09-10
EP3669892C0 (en) 2024-05-08
US9676819B2 (en) 2017-06-13
US12569431B2 (en) 2026-03-10
JP2025143357A (ja) 2025-10-01
JP2017061504A (ja) 2017-03-30
PL2618842T3 (pl) 2019-10-31
CN103189072B (zh) 2018-02-09
EP3669892B1 (en) 2024-05-08
ES2735274T3 (es) 2019-12-17
JP2023113902A (ja) 2023-08-16
JP2019167369A (ja) 2019-10-03
DK2618842T3 (da) 2019-07-01
EP2618842A1 (en) 2013-07-31
EP3669892A1 (en) 2020-06-24
US20130230544A1 (en) 2013-09-05
US20220296505A1 (en) 2022-09-22
AU2011305061A1 (en) 2013-05-02
EP2618842B1 (en) 2019-04-24
CA2811957C (en) 2019-04-16
JP2021130713A (ja) 2021-09-09
EP3520814A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
PL3669892T3 (pl) Kompozycja do zastosowania w metodzie immunostymulacyjnej
SG2014010706A (en) Method and composition
GB201016001D0 (en) Composition and method
GB201001833D0 (en) Method
GB201007353D0 (en) Method
GB201004759D0 (en) Method
GB201007354D0 (en) Method
GB201011513D0 (en) Method
GB201003531D0 (en) Composition and method
EP2601936A4 (en) COMPRESSED COMPOSITION
GB201006306D0 (en) Method
GB201012148D0 (en) Method
GB201008364D0 (en) Composition and method
GB201012784D0 (en) Method
GB201010855D0 (en) Method
GB201008843D0 (en) Method and composition
GB201007207D0 (en) Method
PL119426U1 (pl) Ławka
IL223436A (en) Methods for preparing tetranor - pgdm and tetranor - pgjm
GB201017003D0 (en) Method
GB201007522D0 (en) Method
IL225307A0 (en) A method for the preparation of rumi urine
GB201004097D0 (en) Improvements in packaging
PH32009000131S1 (en) Bench
GB201004169D0 (en) Method